Clinical trial
Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally…
NCT00049114 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00049114 |
|---|---|
| Title | Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer |
| Official title | A Phase I-II Study of R115777 (ZARNESTRA) Plus Doxorubicin and Cyclophosphamide in Patients With Locally Advanced Breast Cancer and Metastatic Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Inflammatory Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer |
| Intervention type | Biological, Drug, Other, Procedure |
| Interventions | doxorubicin hydrochloride, cyclophosphamide, tipifarnib, filgrastim, therapeutic conventional surgery, laboratory biomarker analysis |
| Enrollment | 62 |
| Start date | Feb 1, 2003 |
| Primary completion | Jan 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 6, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: